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Abstract
Background: Haemophilus parasuis is the causative agent of Glässer’s disease in pigs. Currently, little is known
about the molecular mechanisms that contribute to disease susceptibility. This study used a porcine
oligonucleotide microarray to identify genes that were differentially expressed (DE) in the lungs of colostrum-
deprived animals previously characterized as being either ‘Fully Resistant’ (FR) or ‘Susceptible’ to infection by
H. parasuis in a bacterial challenge experiment.
Results: Gene expression profiles of ‘FR’ and ‘Susceptible’ animals were obtained by the identification of genes that
were differentially expressed between each of these groups and mock-inoculated ‘Control’ animals. At 24 hours
post-inoculation, a total of 21 and 58 DE genes were identified in ‘FR’ and ‘Susceptible’ animals respectively. At
72 hours, the numbers of genes were 20 and 347 respectively. ‘FR’ animals at 24 hours exhibited an increased
expression of genes encoding extracellular matrix and TGF-b signalling components, possibly indicative of tissue
repair following the successful early resolution of infection. The gene expression profile of ‘FR’ animals at 72 hours
supported the hypothesis that higher levels of antibacterial activity were responsible for the ‘FR’ phenotype,
possibly due to an increase in natural immunoglobulin A and decrease in signalling by the immunoregulatory
transcription factor peroxisome proliferator-activated receptor gamma (PPAR-g). The expression profile of
‘Susceptible’ animals at both time-points was characterized by an imbalance in signalling between pro and
anti-inflammatory cytokines and an increased expression of genes involved in biological processes associated with
inflammation. These include the pro-inflammatory cytokine genes resistin (RETN) and interleukin 1-beta (IL1B).
At 72 hours, a reduction in the expression of genes involved in antigen presentation by both MHC class I and II
molecules was observed, which could have contributed to the inability of ‘Susceptible’ animals to clear infection.
Conclusions: This study is the first to have identified discrete sets of DE genes in pigs of differing susceptibility to
H. parasuis infection. Consequently, several candidate genes and pathways for disease resistance or susceptibility
phenotypes have been identified. In addition, the findings have shed light on the molecular pathology associated
with Glässer’s disease.
Background
Glässer’s disease in swine is caused by the bacterium
Haemophilus parasuis. This bacterium is commonly iso-
lated from the upper respiratory tract of healthy pigs.
However, in some animals the bacterium can breach the
mucosal epithelium and spread systemically to cause
disease, by means that are poorly understood [1]. Gläs-
ser’s disease is characterized by polyserositis, arthritis
and meningitis. It can be fatal and typically affects pigs
6-8 weeks of age. Fifteen serotypes of H. parasuis
exhibiting varying degrees of virulence can be identified
using the ‘Kielstein and Rapp-Gabrielson’ scheme [2].
However, approximately 30% of field strains are untyp-
able by this method, and there is no absolute correlation
between virulence and serotype, an indication of the
high heterogeneity of H. parasuis isolates [3]. Vaccines
against H. parasuis are commercially available, but none
of the vaccines offer comprehensive protection against
all heterologous strains, and are occasionally ineffective
against homologous strains as well [4-6]. Consequently,
there is a need to investigate other methods of control-
ling the disease such as improving the disease resistance
of pig populations through marker assisted selection.
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It is clear that the immune status of the piglet is cri-
tically important in determining the outcome of
H. parasuis infection. Attempts to reproduce Glässer’s
disease experimentally have only been consistently suc-
cessful when using animals from specific pathogen free
(SPF) herds or colostrum-deprived (CD) piglets [7-10].
These results underscore the importance of antibodies
to H. parasuis in conferring protection from disease.
Indeed, the role of maternal immunity in the protec-
tion of neonatal pigs has recently been demonstrated
[11,12]. It has been postulated that the vulnerability to
infection of animals aged 6-8 weeks is due to a decline
in the amount of circulating maternal antibody post-
weaning. Pigs that are exposed to H. parasuis at an
earlier age, and are protected initially by maternal
immunity, have sufficient time to develop their own
antibody response to the bacterium [1]. There is evi-
dence that the controlled early exposure of pigs to the
prevalent farm strain of H. parasuis can reduce mor-
tality levels, however there are concerns about expos-
ing young pigs to live, virulent bacteria with this
method [13].
Blanco et al. observed large differences in susceptibil-
ity to Glässer’s disease in CD animals inoculated with
pathogenic H. parasuis under identical conditions, indi-
cating that susceptibility to the disease may also have a
genetic component [12]. In a larger scale challenge
experiment, the 21 day old CD offspring of 6 different
sires were either inoculated with H. parasuis or mock-
inoculated with saline. Approximately equal numbers of
animals were euthanized at 24, 48, and 72 hours post-
inoculation and categorized into different disease sus-
ceptibility categories based on scores for the presence of
bacteria, lesions, and clinical signs associated with the
disease [14]. The goal of this current study was to
extend the work of Blanco et al. [14] by using micro-
arrays to define gene expression profiles of piglets iden-
tified in that study as exhibiting low (‘Fully Resistant’) or
high (’Susceptible’) susceptibility to Glässer’s disease at
early (24 hours) and late (72 hours) stages of the chal-
lenge experiment. Since all pigs were challenged by
intra-tracheal inoculation, the investigation focussed on
lung tissue.
Microarrays have recently been employed successfully
to identify the molecular pathways involved in the pig
response to a number of different microbial pathogens
and to identify disease resistance candidate genes
[15-18]. In addition to characterizing the host response
to H. parasuis infection in animals of differing suscept-
ibility, this project aimed to identify the pathways
involved in the molecular pathology associated with
Glässer’s disease.
Results
Validation of infection status in the lungs of ‘FR’,
‘Susceptible’, and ‘Control’ pigs
In the study of Blanco et al. [14], pigs classified as ‘Fully
Resistant’ had no H. parasuis present at internal sites
typically affected by the disease, including the lung, as
determined by bacterial culture or PCR. In addition,
only minor clinical signs or limited pathology at a small
number of sites were permitted. In contrast, ‘Suscepti-
ble’ animals exhibited multiple lesions and clinical signs
of Glässer’s disease, and bacteria were isolated from sev-
eral internal sites by both culture and PCR. Prior to car-
rying out microarray experiments, the absence of
detectable H. parasuis in the lungs of each of the ‘FR’
and ‘Control’ animals, and its presence in ‘Susceptible’
animals, was confirmed by RT-PCR using primers for
H. parasuis 16 S rRNA [19]. A positive control RT-PCR
performed using pig b-actin primers confirmed that the
failure to detect 16 S rRNA transcripts in the ‘FR’ and
‘Control’ animals was not due to a failure of reverse-
transcription (Figure 1). The sensitivity of the RT-PCR
test was estimated to be 0.5 bacterial cells using a dilu-
tion series of H. parasuis RNA spiked into mock-inocu-
lated ‘Control’ pig lung total RNA carried out in
triplicate (data not shown). This was an improvement
on the sensitivity of the original PCR test (estimated to
be 102 bacterial cells), and strengthened the case for
‘FR’ animals having no viable H. parasuis in lung tissue.
The limit of sensitivity of this test is consistent with
other RT-PCR tests for microbial species [20,21].
Overview of gene expression in ‘FR’ and ‘Susceptible’
pigs
Two ‘FR’ and ‘Susceptible’ individuals at 24 hours, and 4
‘FR’ and ‘Susceptible’ individuals at 72 hours post-inocu-
lation, were chosen for microarray experiments. The
‘FR’ and ‘Susceptible’ animal groups were matched for
sire. Gene expression in the lungs of individual ‘FR’ or
‘Susceptible’ individuals was compared to that in a refer-
ence RNA made from 3 or 6 mock-inoculated,
sire-matched ‘Control’ animals at the 24 and 72 hour
time-points respectively. It was not possible to use mul-
tiple ‘Control’ animals for the same sire and time-point
in the pools as only one animal from each sire at each
time-point was designated as a ‘Control’ animal in the
original challenge experiments. Therefore pools were
made from samples from ‘Control’ animals of the same
sire but a mixture of time-points (24, 48, and 72 hours).
A list of the animals used is provided in Table 1. In this
design the reference samples are of biological interest
and therefore direct comparisons of ‘FR’ and ‘Control’
animals, and ‘Susceptible’ and ‘Control’ animals; and the
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Figure 1 Validation of H. parasuis infection status in ‘Fully Resistant’, ‘Susceptible’ and mock-inoculated ‘Control’ animals. RT-PCR using
H. parasuis 16 S rRNA and pig b-actin primers on RNA from (A) mock-inoculated ‘Control’ animals, (B) ‘Fully Resistant’ animals and (C)
‘Susceptible’ animals. L denotes the DNA ladder lane. The number above each lane denotes the animal tested. For example lane 1 in panel A
denotes animal C1; lane 5 in panel C denotes animal S5. The 16 S rRNA amplicon is 821 bp in size when either genomic DNA or cDNA is used
as template. The b-actin amplicon is 182 bp in size when cDNA is used as template and 280 bp when genomic DNA is used. The sizes of
molecular standards in the DNA ladder are indicated for comparison with amplicon sizes. PCR and RT-PCR controls for (D) 16 S rRNA and (E) b-
actin reactions are also provided. The lower case letter above each lane denotes a specific control. For panel D: (a) RT-PCR on uninfected pig
RNA. (b) No reverse transcriptase RT-PCR on uninfected pig DNA. (c) PCR on pig genomic DNA. (d) RT-PCR on H. parasuis RNA. (e) PCR on H.
parasuis genomic DNA. (f) PCR negative control. For panel E: (a) RT-PCR on H. parasuis RNA. (b) PCR on H. parasuis genomic DNA. (c) RT-PCR on
uninfected pig RNA. (d) PCR on pig genomic DNA. (e) No reverse transcriptase RT-PCR on uninfected pig RNA. (f) PCR negative control. Results
shown are from one of two independent replicate RT-PCR experiments.
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indirect comparison of ‘FR’ and ‘Susceptible’ animals
were made during analysis. At each time-point (24 and
72 hours post inoculation), 4 comparisons of differential
gene expression were carried out: ‘Fully Resistant’ v
‘Control’ (FR v C), ‘Susceptible’ v ‘Control’ (S v C),
‘Fully Resistant’ v ‘Susceptible’ (FR v S), and ‘Susceptible’
v ‘Fully Resistant’ (S v FR). The last two comparisons
are actually from the same analysis; the expression ratios
calculated for each gene are the inverse of each other, as
the values are dependent on whether the ratio is
expressed in terms of the ‘Fully Resistant’ or ‘Suscepti-
ble’ group. The raw and normalized microarray data
used for these comparisons have been submitted to the
Gene Expression Omnibus (GEO) database (series entry
GSE19126).
The number of DE genes identified in each of these
comparisons is shown in Table 2, while complete gene
lists for each of the comparisons are provided in addi-
tional files 1 and 2. At 24 hours, roughly similar num-
bers of DE genes were identified in the FR v C and FR v
S (or S v FR) comparisons, 95 and 109 respectively,
while a slightly larger number of DE genes, 149, were
identified in the S v C comparison. At 72 hours, only
41 genes were differentially expressed in the FR v C
comparison. In contrast, a total of 557 and 602 DE
genes were found in the S v C and FR v S (or S v FR)
comparisons respectively.
Expression profiles of ‘FR’ and ‘Susceptible’ animals
The lists of DE genes generated by microarray analyses
were subsequently used to identify the subset of genes
that were differentially expressed in ‘Fully Resistant’ ani-
mals compared to both ‘Control’ and ‘Susceptible’ (i.e.
differentially expressed in the FR v C and FR v S com-
parisons), and ‘Susceptible’ animals compared to both
‘Control’ and ‘Fully Resistant’ (i.e. differentially
expressed in the S v C and S v FR comparisons) at both
24 and 72 hours post inoculation. These genes defined
the expression profiles of ‘Fully Resistant’ and ‘Suscepti-
ble’ animals, and were deemed to be of particular inter-
est for their potential to be differently regulated in
response to infection in ‘Fully Resistant’ and ‘Suscepti-
ble’ animals. The shorthand convention X/Y is used to
denote a gene that is differentially expressed between X
and Y. Expression of DE genes is described as being
either higher or lower in X/Y e.g. higher in FR/C and
Table 1 Animals used for microarray experiments
Animal Sire Time point (hrs) Susceptibility Classification
24 hour time-point microarray experiment
R5 H78 24 Fully Resistant
R6 H78 24 Fully Resistant
S5 H78 24 Fully Susceptible
S6 H78 24 Fully Susceptible
C7 H78 24 Control
C8 H78 48 Control
C9 H78 72 Control
72 hour time-point microarray experiment
R1 H92 72 Fully Resistant
R2 H92 72 Fully Resistant
R3 H77 72 Fully Resistant
R4 H77 72 Fully Resistant
S1 H92 72 Fully Susceptible
S2 H92 72 Fully Susceptible
S3 H77 72 Less Susceptible
S4 H77 72 Less Susceptible
C1 H92 24 Control
C2 H92 48 Control
C3 H92 72 Control
C4 H77 24 Control
C5 H77 48 Control
C6 H77 72 Control
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FR/S indicates a gene whose expression is higher in ‘FR’
animals compared to both ‘Control’ and ‘Susceptible’
animals. Complete lists of the DE genes in these expres-
sion profiles are provided in additional files 3 and 4, and
summarized in Tables 3, 4, 5, 6, and 7. The terms ‘upre-
gulated’ and ‘downregulated’ are avoided because the
use of tissue samples precluded the ability to distinguish
between expression differences caused by enhancement
or repression of transcription or alterations in the pro-
portions of different cell types in the sample. Gene
Ontology (GO) terms that were statistically over-repre-
sented among genes annotated in these lists were
assumed to be of potential functional significance.
Expression profile of ‘FR’ animals
In total, 28 transcripts representing 21 genes were found
to be differentially expressed between ‘FR’ animals and
‘Control’ and ‘Susceptible’ animals at 24 hours. Expres-
sion of 13 genes was higher in ‘FR’ animals than ‘Sus-
ceptible’ and ‘Control’ animals (FR/C and FR/S), while
expression of 8 genes was lower. Human GO annotation
was available for 18 genes. At 72 hours, 21 transcripts
representing 20 genes were differentially expressed, of
which 17 had associated GO annotation. Expression of 5
of these genes was higher in FR/C and FR/S whereas
expression of 15 genes was lower. Lists of the DE genes
that constitute the ‘FR’ expression profile at the 24 and
72 hour time-points are presented in Tables 3 and 4
respectively. Two genes, APOD and RBP4, are common
to both lists.
Eight of the genes whose expression was higher in FR/
C and FR/S at 24 hours are associated with the GO
annotation term ‘proteinaceous extracellular matrix’
(GO:0005578). This GO term was found to be statisti-
cally over-represented among genes whose expression
was higher in ‘FR’ animals at 24 hours (p = 1.33 × 10-
11). The genes are COL1A2, COL3A1, COL6A3,
COL15A1, EFEMP2, LTBP4, TGFBI, and TNC. Four of
these genes encode types of collagen. Two genes whose
expression was lower in FR/C and FR/S at 24 hours,
APOD and RBP4, encode lipocalin molecules. These two
genes are associated with the GO molecular function
ontology term ‘retinol binding’ (GO:0005501) that was
significantly over-represented among genes whose
expression was lower in ‘FR’ animals (p = 3.16 × 10-4).
Another term that was significantly enriched among this
group of genes was ‘response to unfolded protein’
(GO:0006986; p = 1.98 × 10-4). Two heat shock proteins
in the list, DNAJB1 and HSPA6, are associated with this
term.
At 72 hours, two genes whose expression was higher
in FR/C and FR/S were proteinaceous extracellular
matrix (ECM) components: COL1A1 and POSTN. As at
24 hours, this term was found to be statistically over-
represented among the group of genes whose expression
was higher in ‘FR’ animals at this time-point (p = 9.13 ×
10-3). Another more highly expressed transcript matched
the coding sequence of the constant region of immuno-
globulin A (IgA). Expression of the lipocalin genes
APOD and RBP4 was lower in FR/C and FR/S at 72
hours, as it was at 24 hours. Again, the term ‘retinol
binding’ was significantly enriched in the gene list (p =
2.25 × 10-3). Literature searches revealed that several of
the genes whose expression was lower in FR/C and FR/
S have been shown to either regulate or be regulated by
the lipid-binding transcription factor Peroxisome prolif-
erator-activated receptor gamma (PPAR-g) in man.
These genes are NUPR1, PDK4, and TXNIP [22-24].
Other DE genes which function in retinoid and lipid
transport are ABCA6 and CRABP2.
Table 2 Number of differentially expressed (DE) genes across all microarray comparisons
Comparison Gene expression difference No. of DE genes at
24 hours
No. of DE genes at
72 hours
Fully Resistant v Control
(FR v C)
More highly expressed in FR than C 46 6
Less highly expressed in FR than C 49 35
Total number of DE genes 95 41
Susceptible v Control
(S v C)
More highly expressed in S than C 81 191
Less highly expressed in S than C 68 366
Total number of DE genes 149 557
Fully Resistant v Susceptible or Susceptible
v Fully Resistant
(FR v S or S v FR)
More highly expressed in FR than S or less highly
expressed in S than FR
64 337
Less highly expressed in FR than S or more highly
expressed in S than FR
45 265
Total number of DE genes 109 602
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Table 3 Differentially expressed (DE) genes in the expression profile of ‘Fully Resistant’ animals 24 hours post-
inoculation
Genes grouped by function Genbank human RefSeq ID FR v C fold change FR v S fold change
More highly expressed in ‘Fully Resistant’ animals
Extracellular matrix components
Tenascin C (TNC) NM_002160 +2.30 +4.20
TGF-b-induced (TGFBI) NM_000358 +2.20 +4.69
Latent TGF-b binding protein 4 (LTBP4) NM_003573 +2.07 +2.41
Collagen, type I, alpha 2 (COL1A2) NM_000089 +2.03 +2.57
EGF-containing fibulin-like extracellular matrix protein 2 (EFEMP2) NM_016938 +1.95 +2.01
Collagen, type III, alpha 1 (COL3A1) NM_000090 +1.85 +2.43
Collagen, type XV, alpha 1 (COL15A1) NM_001855 +1.84 +2.46
Collagen, type VI, alpha 3 (COL6A3) NM_057167 +1.77 +2.33
Other
X (inactive)-specific transcript (XIST) NR_001564 +2.89 +8.06
Slit homolog 3 (SLIT3) NM_003062 +2.06 +2.57
Prolylcarboxypeptidase (PRCP) NM_005040 +1.89 +2.60
Coiled-coil domain containing 80 (CCDC80) NM_199512 +1.83 +2.43
Oligo SS00010557 (no significant hit to known gene) NONE +1.78 +3.36
Less highly expressed in ‘Fully Resistant’ animals
Retinoid-binding
Retinol binding protein 4 (RBP4) NM_006744 -2.51 -6.54
Apolipoprotein D (APOD) NM_001647 -1.80 -2.43
Heat shock proteins
DnaJ, subfamily B, member 1 (DNAJB1) NM_006145 -2.03 -3.51
Heat shock 70kDa protein 6 (HSPA6) NM_002155 -2.20 -3.32
Lipid mobilization and metabolism
Lipoprotein Lipase (LPL) NM_000237 -1.92 -5.05
Other
Oligo SS00011159 (no significant hit to known gene) NONE -1.77 -3.58
Transcobalamin I (TCN1) NM_001062 -1.82 -4.63
DEAD box polypeptide 3, X-linked (DDX3X) NM_001356 -2.22 -2.36
A list of all genes that were differentially expressed in both the ‘FR v C’ and ‘FR v S’ comparisons 24 hours post-inoculation. Gene names were assigned on the
basis of the best sequence match to a human gene identified by BLAST. Genes highlighted in bold are annotated with the ‘GO’ terms listed in the Results
section. Genes not in bold type face were identified as having a particular function through literature searches. Genes are arranged in groups of related function.
Fold changes are expressed with respect to the ‘FR’ animals. Gene expression is either higher (+) or lower (-) in ‘FR’ animals compared to ‘Control’ and
‘Susceptible’ animals (BH corrected p < 0.05).
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Table 4 Differentially expressed (DE) genes in the expression profile of ‘Fully Resistant’ animals 72 hours post-
inoculation
Genes grouped by function Genbank human RefSeq ID FR v C fold change FR v S fold change
More highly expressed in ‘Fully Resistant’ animals
Extracellular matrix components
Collagen, type I, alpha 1 (COL1A1) NM_000088 +2.55 +3.94
Periostin (POSTN) NM_006475 +1.84 +3.16
Immunoglobulin
Immunoglobulin alpha heavy chain constant region (IGHA) NONE +2.03 +1.82
Retinoid-binding
Cellular retinoic acid binding protein 2 (CRABP2) NM_001878 +1.97 +2.23
Other
Mortality factor 4 like 1 (MORF4L1) NM_206839 +1.75 +2.64
Less highly expressed in ‘Fully Resistant’ animals
Retinoid binding
Apolipoprotein D (APOD) NM_001647 -2.04 -4.59
Retinol binding protein 4 (RBP4) NM_006744 -2.36 -4.92
PPAR-g regulators/regulated
Thioredoxin interacting protein (TXNIP) NM_006472 -1.87 -2.43
Nuclear protein 1 (NUPR1) NM_012385 -2.06 -1.75
Pyruvate dehydrogenase kinase, isoenzyme 4 (PDK4) NM_002612 -2.33 -1.89
Lipid mobilization and metabolism
ATP-binding cassette, sub-family A, member 6 (ABCA6) NM_172346 -2.69 -2.81
Other
Ubiquitin-conjugating enzyme E2L 6 (UBE2L6) NM_004223 -1.78 +2.63
Annexin A8 like 2 (ANXA8L2) NM_001630 -1.84 -2.73
Pre-mRNA cleavage complex II protein (PCF2) NM_015885 -1.84 -3.27
Proprotein convertase subtilisin/kexin type 6 (PCSK6) NM_138319 -1.85 -2.91
Glutathione S-transferase M3 (GSTM3) NM_000849 -1.91 -1.99
BTG family, member 2 (BTG2) NM_006763 -1.92 -2.85
Calnexin (CANX) NM_001746 -2.30 -2.03
Thymosin like 3 (TMSL3) NM_183049 -5.28 -4.86
Porcine endogenous retrovirus type C (PERV-C) NONE -7.11 -3.41
A list of all DE genes identified in both the FR v C and FR v S comparisons 72 hours post-inoculation. Gene names were assigned on the basis of the best
sequence match to a human gene identified by BLAST. Genes highlighted in bold are annotated with the ‘GO’ terms listed in the Results section. Genes not in
bold type face were identified as having a particular function through literature searches. Genes are arranged in groups of related function. Fold changes are
expressed with respect to the ‘FR’ animals. Gene expression was either higher (+) or lower (-) in ‘FR’ animals compared to ‘Control’ and ‘Susceptible’ animals (BH
corrected p < 0.05).
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Table 5 Selected differentially expressed (DE) genes in the expression profile of ‘Susceptible’ animals 24 hours post-
inoculation
Genes grouped by function Genbank human RefSeq ID S v C fold change S v FR fold change
More highly expressed in ‘Susceptible’ animals
Pro inflammatory cytokine/cytokine receptors
Colony stimulating factor 3 receptor (CSF3R) NM_172313 +5.99 +5.68
S100 calcium binding protein A9 (S100A9) NM_002965 +5.40 +6.70
S100 calcium binding protein A12 (S100A12) NM_005621 +3.45 +3.38
Pleiotrophin (PTN) NM_002825 +2.97 +2.75
Chemokine (C-X-C motif) ligand 2 (CXCL2) NM_002089 +2.79 +2.84
Anti inflammatory cytokine/cytokine receptors
Interleukin 10 (IL10) NM_000572 +2.68 +4.29
CD163 antigen (CD163) NM_203416 +2.65 +3.07
Neutrophil granule/phagocytosis proteins
Lactotransferrin (LTF) NM_002343 +16.47 +9.19
Matrix metalloproteinase 9 (MMP9) NM_004994 +3.87 +4.89
Transcobalamin I (TCN1) NM_001062 +2.55 +4.64
Acyloxyacyl hydrolase (AOAH) NM_001637 +2.12 +2.04
Lipid mobilization and metabolism
Resistin (RETN) NM_020415 +12.77 +15.04
Solute carrier family 2 member 3 (SLC2A3) NM_006931 +3.36 +2.89
Alpha-2-glycoprotein 1, zinc binding (AZGP1) NM_001185 +2.83 +3.72
Lipoprotein lipase (LPL) NM_000237 +2.62 +5.05
Retinol binding protein 4 (RBP4) NM_006744 +2.60 +6.54
Less highly expressed in Susceptible animals
Extracellular matrix components
Fibronectin 1 (FN1) NM_212482 -1.89 -2.84
Dermatopontin (DPT) NM_001937 -2.11 -2.35
Transforming growth factor, beta-induced, (TGFBI) NM_000358 -2.13 -4.68
Microfibrillar associated protein 5 (MFAP5) NM_003480 -2.14 -2.43
Elastin (ELN) NM_000501 -4.54 -3.82
Extracellular matrix growth factors
Transforming growth factor beta 2 (TGFB2) NM_003238 -2.35 -3.58
P311 protein (P311) NM_004772 -4.14 -4.5
List of selected genes that were differentially expressed in both the S v C and S v FR comparisons 24 hours post-inoculation. Genes highlighted in bold are
annotated with the ‘GO’ terms listed in the Results section. Genes not in bold type face were identified as having a particular function through literature
searches. Genes are arranged in groups of related function. Fold changes are expressed with respect to ‘Susceptible’ animals. Gene expression was either higher
(+) or lower (-) in ‘Susceptible’ animals compared to ‘Control’ and ‘FR’ animals (BH corrected p < 0.05).
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Table 6 Selected genes that are more highly expressed in ‘Susceptible’ than ‘Fully Resistant’ and ‘Control’ animals at
72 hours post-inoculation
Genes grouped by function Genbank human RefSeq ID S v C fold change S v FR fold change
Pro-inflammatory cytokine/cytokine receptors
S100 calcium binding protein A9 (S100A9) NM_002965 +8.43 +9.91
Interleukin 1 beta (IL1B) NM_000576 +5.65 +4.01
S100 calcium binding protein A12 (S100A12) NM_005621 +3.76 +4.4
Chemokine (C-X-C motif) ligand 2 (CXCL2) NM_002089 +2.45 +2.32
Interleukin 8 (IL8) NM_000584 +2.21 +3.45
Anti-inflammatory cytokine/cytokine receptors
CD163 antigen (CD163) NM_203416 +2.71 +2.49
Interleukin 1 receptor antagonist (IL1RN) NM_173843 +2.31 +2.70
Interleukin 4 receptor (IL4R) NM_000418 +2.27 +1.93
Neutrophil granule/phagocytosis proteins
Cathelicidin antimicrobial peptide (CAMP) NM_004345 +5.30 +10.41
Matrix metalloproteinase 9 (MMP9) NM_004994 +5.09 +4.19
Transcobalamin I (TCN1) NM_001062 +4.48 +4.10
Chitinase 3-like 1 (CHI3L1) NM_001276 +4.48 +4.84
Solute carrier family 11 member A1 (SLC11A1) NM_000578 +3.38 +2.54
Cathepsin L (CTSL) NM_145918 +3.19 +3.01
Neutrophil cytosolic factor 1 (NCF1) NM_000265 +2.61 +2.07
Cytochrome b-245, beta polypeptide (CYBB) NM_000397 +2.11 +1.96
Ras-related C3 botulinum toxin substrate 1 (RAC1) NM_006908 +2.07 +1.86
Cathepsin C (CTSC) NM_148170 +2.07 +2.29
Lipid mobilization and metabolism
Resistin (RETN) NM_020415 +12.96 +12.24
Adrenergic, alpha-2A-, receptor (ADRA2A) NM_000681 +3.71 +3.85
Lipoprotein lipase (LPL) NM_000237 +3.70 +4.54
Benzodiazapine receptor (peripheral) (BZRP) NM_000714 +2.55 +3.10
Apolipoprotein D (APOD) NM_001647 +2.25 +4.59
PDZK1 interacting protein 1 (PDZK1IP1) NM_005764 +2.15 +2.48
Angiopoietin-like 4 (ANGPTL4) NM_139314 +2.14 +3.07
Retinol binding protein 4 (RBP4) NM_006744 +2.10 +4.94
Lipid biosynthesis
Solute carrier family 2, member 3 (SLC2A3) NM_006931 +4.03 +4.11
Leukotriene A4 hydrolase (LTA4H) NM_000895 +3.11 +3.28
Thromboxane A synthase 1 (TBXAS1) NM_030984 +2.24 +1.97
Prostaglandin-endoperoxide synthase 1 (PTGS1) NM_080591 +1.95 +2.11
Arachidonate 5-lipoxygenase-activating protein (ALOX5AP) NM_001629 +1.94 +2.35
Acyl-CoA synthetase long-chain family member 4 (ACSL4) NM_022977 +2.07 +2.06
1-acylglycerol-3-phosphate O-acyltransferase 6 (AGPAT6) NM_178819 +2.31 +2.52
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Table 6: Selected genes that are more highly expressed in ‘Susceptible’ than ‘Fully Resistant’ and ‘Control’ animals at
72 hours post-inoculation (Continued)
Coagulation
Thrombospondin 1 (THBS1) NM_003246 +2.79 +3.36
Serine proteinase inhibitor, clade E, member 1 (SERPINE1) NM_000602 +2.49 +2.55
Adaptor-related protein complex 3, delta 1 subunit (AP3D1) NM_003938 +2.24 +2.28
Tumor necrosis factor, alpha-induced protein 6 (TNFAIP6) NM_007115 +2.63 +2.90
Thromboxane A synthase 1 (TBXAS1) NM_030984 +2.24 +1.97
Phospholipid scramblase 4 (PLSCR4) NM_020353 +2.02 +2.86
List of selected genes that are more highly expressed in ‘Susceptible’ than ‘FR’ and ‘Control’ animals 72 hours post-inoculation. Genes are arranged in groups of
related function. Genes highlighted in bold are annotated with the ‘GO’ terms listed in the Results section. Genes not in bold type face were identified by as
having a particular function through literature searches. Fold changes are expressed with respect to ‘Susceptible’ animals (BH corrected p < 0.05).
Table 7 Selected genes that are less highly expressed in ‘Susceptible’ than ‘Fully Resistant’ and ‘Control’ animals at 72
hours post-inoculation
Genes grouped by function Genbank human RefSeq ID S v C fold change S v FR fold change
Extracellular matrix components
Fibronectin type III domain containing 1 (FNDC1) NM_032532 -1.78 -1.86
Collagen, type VI, alpha 3 (COL6A3) NM_057167 -1.82 -2.52
Fibronectin type III domain containing 3 (FNDC3) NM_014923 -1.83 -2.46
Decorin (DCN) NM_133503 -1.98 -1.88
Extracellular matrix protein 2 (EMP2) NM_001393 -2.18 -2.50
EGF-containing fibulin-like extracellular matrix protein 1 (EFEMP1) NM_018894 -2.2 -2.78
Secreted protein, acidic, cysteine-rich (SPARC) NM_003118 -2.2 -2.78
Matrilin 2 (MATN2) NM_030583 -2.35 -2.7
Collagen, type I, alpha 1 (COL1A1) NM_000088 -2.38 -3.39
Collagen, type III, alpha 1 (COL3A1) NM_000090 -2.52 -3.65
Fibronectin 1 (FN1) NM_212482 -2.52 -3.29
Dermatopontin (DPT) NM_001937 -2.73 -2.75
Transforming growth factor, beta-induced (TGFBI) NM_000358 -3.02 -3.79
Lectin, galactoside-binding, soluble, 3 binding protein (LGALS3BP) NM_005567 -3.2 -3.09
Asporin (ASPN) NM_017680 -3.38 -3.66
Microfibrillar associated protein 5 (MFAP5) NM_003480 -5.54 -4.58
ECM growth factor ligand/receptor
Bone morphogenetic protein receptor, type II (BMPR2) NM_033346 -1.76 -2.07
Insulin-like growth factor binding protein 5 (IGFBP5) NM_000599 -1.76 -2.17
Fibroblast growth factor 17 (FGF17) NM_003867 -2.03 -2.72
WNT family, member 5A (WNT5A), mRNA NM_003392 -2.16 -2.14
P311 protein (P311) NM_004772 -6.98 -9.01
Antigen presentation
Proteasome subunit, beta type, 8 (PSMB8) NM_148919 -2.06 -1.83
CD1B antigen, b polypeptide (CD1B) NM_001764 -2.11 -2.40
Major histocompatibility complex, class II, DM alpha (HLA-DMA) NM_006120 -2.18 -1.83
Major histocompatibility complex, class II, DR alpha (HLA-DRA) NM_019111 -2.3 -2.31
Cathepsin S (CTSS) NM_004079 -2.32 -1.94
Wilkinson et al. BMC Genomics 2010, 11:455
http://www.biomedcentral.com/1471-2164/11/455
Page 10 of 22
Expression profile of ‘Susceptible’ animals
In the ‘Susceptible’ animals at 24 hours, a total of 60
transcripts representing 58 genes were found to be dif-
ferentially expressed compared to both ‘Control’ and
‘Fully Resistant’ pigs. Human GO annotation was avail-
able for 53 genes. Expression of 32 genes was higher in
S/C and S/FR whereas expression of 21 genes was
lower. Approximately 60% of these genes were also
found to be differentially expressed at 72 hours in the
same direction, indicating that there is considerable
similarity in expression profiles at the two time-points.
At the 72 hour time-point, 384 transcript sequences
from 347 genes were differentially expressed, with
human GO annotation available for 293 genes. Expres-
sion of 136 genes was higher in S/C and S/FR whereas
expression of 248 genes was lower. Lists of selected DE
genes in the expression profile of ‘Susceptible’ animals
at 24 and 72 hours post-inoculation are provided in
Tables 5, 6, and 7.
At 24 hours, several GO terms associated with the
immune system were significantly over-represented
among the group of genes whose expression was higher
in ‘Susceptible’ animals than both ‘Control’ and ‘FR’ ani-
mals (S/C and S/FR). These were ‘defence response’
(GO:0006592; p = 9.3 × 10-6), ‘inflammatory response’
(GO:0006954; p = 2.88 × 10-5), ‘response to wounding’
(GO:0009611; p = 2.04 × 10-4), ‘response to bacterium’
(GO:0009617; p = 6.30 × 10-3), and ‘leukocyte chemo-
taxis’ (GO:0030595; p = 8.28 × 10-3). A large proportion
of the most highly differentially expressed genes are
Table 7: Selected genes that are less highly expressed in ‘Susceptible’ than ‘Fully Resistant’ and ‘Control’ animals at
72 hours post-inoculation (Continued)
Major histocompatibility complex, class II, DM beta (HLA-DMB) NM_002118 -3.21 -2.93
T cell receptor signaling
T cell receptor alpha locus (TCRA) NONE -2.45 -3.34
Dual specificity phosphatase 14 (DUSP14) NM_007026 -2.50 -1.94
V-set and immunoglobulin domain containing 4 (VSIG4) NM_007268 -2.91 -2.00
GATA binding protein 3 (GATA3) NM_002051 -3.00 -3.22
Immunoglobulin genes
Immunoglobulin J polypeptide (IGJ) NM_144646 -1.90 -2.73
Immunoglobulin kappa chain variable region (IGK) NONE -2.36 -5.05
Anti-viral and type I interferon regulated genes
Interferon regulatory factor 9 (IRF9) NM_006084 -1.82 -2.01
Hect domain and RLD 5 (HERC5) NM_016323 -1.85 -1.95
Interferon regulatory factor 2 binding protein 2 (IRF2BP2) NM_182972 -1.90 -1.95
Interferon induced transmembrane protein 3 (IFITM3) NM_021034 -2.52 -2.08
Tripartite motif protein TRIM5 isoform alpha (TRIM5A) NM_033034 -3.02 -3.00
Myxovirus resistance 1 (MX1) NM_002462 -3.26 -2.58
Interferon-induced protein 44 (IFI44) NM_006820 -3.26 -2.98
Family with sequence similarity 14, member A (FAM14A) NM_032036 -3.75 -2.89
Ubiquitin specific protease 18 (USP18) NM_017414 -3.84 -2.65
2’,5’-oligoadenylate synthetase 1 (OAS1) NM_002534 -3.87 -3.21
Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) NM_001001887 -4.99 -3.04
DEAD box polypeptide 58 (DDX58) NM_014314 -5.30 -3.70
XIAP associated factor-1 (XIAPAF1) NM_017523 -6.07 -5.08
ISG15 ubiquitin like modifier (ISG15) NM_005101 -6.82 -3.85
Interferon, alpha-inducible protein 6 (IFI6) NM_002038 -7.18 -3.63
2’-5’-oligoadenylate synthetase 2 (OAS2) NM_016817 -9.55 -8.96
List of selected genes that are less highly expressed in ‘Susceptible’ than ‘FR’ and ‘Control’ animals 72 hours post-inoculation. Genes are arranged in groups of
related function. Genes highlighted in bold are annotated with the ‘GO’ terms listed in the Results section. Genes not in bold type face were identified by as
having a particular function through literature searches. Fold changes are expressed with respect to ‘Susceptible’ animals (BH corrected p < 0.05).
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associated with an acute inflammatory response to bac-
terial infection. Three groups of genes of related
immune function were identified through literature
searches as having higher expression in S/C and S/FR.
The first group was cytokines and their receptors. Most
of these either promote the functional activities of neu-
trophils, including the phagocytosis of bacteria (such as
CSF3R), or are neutrophil chemokines (such as S100A9)
[25,26]. However, two anti-inflammatory cytokine genes
were also identified: CD163 and IL10. A second group
of genes encode neutrophil granule proteins, such as the
antimicrobial proteins AOAH and LTF, and the secreted
protease MMP9 [27]. The third group contains genes
involved in the uptake and metabolism of lipids. It
includes the most differentially expressed gene in ‘Sus-
ceptible’ animals, RETN, as well as LPL and RBP4, two
genes whose expression was lower in FR/C and FR/S.
The principal over-represented GO term among genes
whose expression was lower in S/C and S/FR was ‘pro-
teinaceous extracellular matrix’ (GO:0005578; p = 1.04
× 10-3). Interestingly, as stated previously, this term was
associated with genes whose expression was higher in
FR/C and FR/S at 24 and 72 hours. The 5 genes anno-
tated under this term were DPT, ELN, FN1, MFAP5,
and TGFBI, and additional ECM components were also
identified in the list by literature searches. Expression of
TGFB2, a member of the transforming growth factor
beta family of genes that promote tissue repair, was also
lower in S/C and S/FR.
Many of the most statistically significant GO terms at
24 hours were also over-represented at 72 hours, but a
larger number of genes were annotated under each GO
term for the latter, a reflection of the increased number
of DE genes identified at this time-point. GO terms
associated with immunology were ‘defence response’
(GO:0006592; p = 5.60 × 10-10), ‘inflammatory response’
(GO:0006954; p = 4.94 × 10-11), ‘response to bacterium’
(GO:0009617; p = 1.42 × 10-3), ‘acute phase response’
(GO:0006953; p = 4.88 × 10-3), ‘leukocyte chemotaxis’
(GO:0030595; p = 2.46 × 10-3), and ‘response to mole-
cule of bacterial origin’ (GO:0002237; p = 9.42 × 10-3).
Among the list of genes whose expression was higher in
S/C and S/FR at 72 hours were additional cytokine
genes, including the well-characterized pro-inflamma-
tory genes IL1B and IL8, and the anti-inflammatory
IL1RN, whose protein is an antagonist of IL-1b [28].
Several other genes encoding neutrophil granule pro-
teins were identified, such as CAMP and CHI3L, as were
3 components of the neutrophil NADPH oxidase that
participates in phagocytosis (CYBB, NCF1, and RAC1)
[29]. More genes involved in lipid metabolism were also
found to be differentially expressed in ‘Susceptible’ ani-
mals at this time-point. The GO terms ‘fatty acid
metabolic process’ (GO:0006631; p = 3.12 × 10-4), ‘icosa-
noid biosynthetic process’ (GO:0046456; p = 9.42 × 10-
3), and ‘prostaglandin biosynthetic process’
(GO:0001516; p = 9.42 × 10-3) were all over-represented
in the expression profile of ‘Susceptible’ animals. The
list includes genes for enzymes that function in the bio-
synthesis of the potent lipid inflammatory mediators
leukotriene B4 (the genes LTA4 H and ALOX5AP) and
thromboxane A2 (the genes TBXAS1 and PTGS1).
Finally, the GO term ‘coagulation’ (GO:0050817; p =
8.78 × 10-3) was significantly over-represented. Genes
annotated with this term include the protease inhibitor
SERPINE1 and the adhesive glycoprotein THSB1 [30,31].
Two groups of related GO terms were statistically
over-represented in the list of genes whose expression
was lower in S/C and S/FR. The first group included
terms relating to ECM, which were also identified in the
expression profile of ‘Susceptible’ animals at 24 hours.
These were ‘proteinaceous extracellular matrix’
(GO:0005578; p = 5.83 × 10-6) and ‘extracellular matrix
part’ (GO:0044420; p = 3.24 × 10-3). The second group
were immunology terms: ‘immune response’
(GO:0006955; p = 1.15 × 10-3), ‘defence response’
(GO:0006952; p = 7.18 × 10-3), and ‘response to virus’
(GO:0009615; p = 8.51 × 10-4). Although the term
‘defence response’ was also over-represented among
genes whose expression was higher in S/C and S/FR, the
genes annotated with this all encompassing term had
different functions. Broadly speaking, two different
groups of genes whose expression was lower in S/C and
S/FR were identified: those involved in antigen presenta-
tion to T cells and those that functioned in antiviral
immunity. The first group contains genes whose pro-
ducts function in either class I or class II presentation
of peptide antigens or presentation of lipid antigens.
Those genes implicated in the former are PSMB8 (class
I), and CTSS, HLA-DMA, HLA-DMB, and HLA-DRA
(class II) [32,33]. CD1B presents lipid antigens. Two
transcripts encoding putative immunoglobulin J and
kappa chains were also found to be less highly expressed
in the ‘Susceptible’ group. The second, and largest,
group contains genes whose products have known anti-
viral activity such as MX1 and OAS2 [34,35]. It also
includes genes that are transcribed in response to signal-
ling by the antiviral type I interferons (e.g. HERC5 and
IFITM3) [36,37].
Verification of microarray data by Reverse Transcription
Quantitative Polymerase Chain Reaction (RT-qPCR)
The microarray results were verified for selected DE
genes by RT-qPCR. A list of the genes and their asso-
ciated primer sequences is provided in additional file 5.
RT-qPCR was carried out for 23 genes selected from
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the expression profiles of ‘FR’ and Susceptible animals.
These genes had been identified as being differentially
expressed in at least two of the comparisons by microar-
ray analysis (FR v C and FR v S, or S v C and S v FR at
24 or 72 hours post-inoculation). The microarray and
RT-qPCR fold changes for DE genes in the ‘FR’ profile
at 24 and 72 hours are shown in Figure 2. Four out of 6
genes tested at 24 hours, produced a normalised expres-
sion ratio of > 1.75:1, in agreement with the microarray
data for both comparisons (FR v C, and FR v S). None
of these differences reached statistical significance for
the FR v C comparison, whereas 4 out of 6 did in the
FR v S comparison. At 72 hours, all 10 RT-qPCR results
were in agreement with the microarray data on fold-
change, with 5 out of 10 being statistically significant.
RT-qPCR results for DE genes in the ‘Susceptible’ pro-
file are shown in Figure 3. All 7 of the genes tested at
24 hours were differentially expressed with a ratio of >
1.75:1; this ratio was significant in 13 out of 14 cases. At
72 hours, the direction of differential expression was in
agreement for all 15 genes across both the S v C and S
v R comparisons, with 18 out of 30 being statistically
significant. Linear regression analysis revealed a strong
correlation between the microarray and RT-qPCR data
for each of the comparisons, with r2 coefficients ranging
from 0.83 to 0.99 (data not shown).
Figure 2 Comparison of relative expression differences for selected genes from the ‘Fully Resistant’ expression profiles determined by
microarray and RT-qPCR. The relative expression fold change for genes identified as being differentially expressed in the (A) FR v C comparison
at 24 hours, (B) FR v S comparison at 24 hours, (C) FR v C comparison at 72 hours, and (D) FR v S comparison at 72 hours. For each gene, the
black bar indicates the fold change as determined by microarray; the grey bar indicates the expression ratio as determined by RT-qPCR, with
associated standard error bars. Relative expression ratios are given as the ratio of the first group compared to the second (e.g. ‘Fully Resistant’
compared to ‘Control’ in the graph in panel A). Statistical significance of the relative expression ratio is indicated (* p < 0.05; ** p < 0.01). Results
for TMSL3 at 72 hours were not plotted on graphs C and D because of the axis scale chosen. The array fold changes for this gene in the FR v C
and FR v S comparisons were -5.26 and -4.85 whereas the RT-qPCR fold changes were -101.75 and -73.47 respectively, the last being statistically
significant (p < 0.05). Primer information is provided in additional file 5.
Wilkinson et al. BMC Genomics 2010, 11:455
http://www.biomedcentral.com/1471-2164/11/455
Page 13 of 22
Discussion
For this study, microarray experiments were carried out
to compare gene expression in lung tissue of animals
that were ‘Fully Resistant’ or ‘Susceptible’ to Glässer’s
disease, together with mock-inoculated ‘Control’ ani-
mals, at 24 and 72 hours post-inoculation. This was
done with the principal aim of identifying candidate
genes responsible for the observed differences in sus-
ceptibility, but also to increase knowledge of the genetic
programmes activated in the host during H. parasuis
infection in affected animals. ‘Fully Resistant’ and ‘Sus-
ceptible’ animals were matched for sire and time-point
to reduce background differences in gene expression not
attributable to differences in infection status. Unfortu-
nately, it was not possible to match multiple mock-
inoculated ‘Control’ animals to ‘FR’ and ‘Susceptible’
animals for both sire and time-point, as only one animal
from each sire was designated as a ‘Control’ animal at
each time-point in the original challenge experiment.
Instead, pools were created from lung RNA from
Figure 3 Comparison of relative expression differences for selected genes from the ‘Susceptible’ expression profiles determined by
microarray and RT-qPCR. The relative expression fold change for genes identified as being differentially expressed in the (A) S v C comparison
at 24 hours, (B) S v FR comparison at 24 hours, (C) S v C comparison at 72 hours, and (D) S v FR comparison at 72 hours. For each gene, the
black bar indicates the expression ratio as determined by microarray; the grey bar indicates the expression ratio as determined by RT-qPCR, with
associated standard error bars. Relative expression ratios are given as the ratio of the first group compared to the second (e.g. ‘Susceptible’
compared to ‘Control’ in the graph in panel A. Statistical significance of the relative expression ratio is indicated (* p < 0.05; ** p < 0.01). Results
for RETN and LTF at 24 hours, and RETN and OAS2 at 72 hours were not plotted because of the axis scale chosen. The array fold changes for
RETN and LTF at 24 hours in the S v C comparison were +12.77 and +16.45 whereas the RT-qPCR fold changes were +53.65 and +24.69
respectively. For the S v FR comparison at 24 hours the array fold changes were +14.93 and +9.13 whereas the RT-qPCR changes were +38.38
and +16.68 respectively. For the S v C comparison at 72 hours, the array fold changes for RETN and OAS2 were +13.00 and -9.58 whereas the RT-
qPCR fold changes were +98.77 and -26.31 respectively. For the S v FR comparison at 72 hours, the array fold changes were +12.24 and -3.58
whereas the RT-qPCR fold changes were +66.20 and -20.00 respectively. All fold changes for RETN, LTF, and OAS2 measured by RT-qPCR were
statistically significant (p < 0.01). Primer information is provided in additional file 5.
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‘Control’ animals of the same sire but different time-
points (24, 48, and 72 hours). It is possible therefore
that some of the DE genes identified in the ‘FR v C’ and
‘S v C’ comparisons could be attributable to a ‘day
effect’ that is independent of differences caused by expo-
sure to H. parasuis. However, this is not the case for the
‘FR v S/S v FR’ comparison, and as the expression pro-
files described in the Results section only contain genes
that were differentially expressed between the group of
interest and both other groups (i.e. for the ‘FR’ expres-
sion profile, genes identified as being differentially
expressed in FR v C and FR v S comparisons; for the
‘Susceptible’ expression profile, genes identified as being
DE in the S v C and S v FR comparisons), genes whose
differential expression is attributable to such a ‘day
effect’ should be absent from the expression profiles.
Overall, the microarray experiments successfully iden-
tified differentially expressed (DE) genes in comparisons
between ‘FR’, ‘Susceptible’, and ‘Control’ animals, as
determined by the good concordance observed between
fold changes determined by microarray and RT-qPCR.
Fold changes for some of the genes did not reach statis-
tical significance when measured by RT-qPCR, particu-
larly for the 24 hour time-point where only 2 biological
replicates were available. However, the direction of
expression differences was the same for 21 out of the 23
genes tested.
The results showed that fewer genes were differentially
expressed between ‘FR’ and ‘Control’ animals (FR v C)
than between ‘Susceptible’ animals and these two groups
(S v C and S v FR). This finding was expected as the
basis for the ‘FR’ susceptibility classification was the
absence of any signs of an ongoing H. parasuis infection
in inoculated pigs, and none of the mock-inoculated
‘Control’ pigs were infected. RT-PCR confirmed the
absence of detectable amounts of H. parasuis in both
‘FR’ and ‘Control’ animals. In contrast, all ‘Susceptible’
animals exhibited multiple signs of infection and had
detectable levels of H. parasuis in lung tissue.
To aid the identification of genes and pathways that
could be involved in disease susceptibility phenotypes,
expression profiles of the ‘FR’ and ‘Susceptible’ animals
were generated for both time-points. These profiles con-
tained only those genes that were differentially
expressed between the group of interest and both other
groups, and therefore potentially contained genes that
were regulated differently in ‘FR’ and ‘Susceptible’ ani-
mals after exposure to H. parasuis. The expression pro-
file of ‘FR’ animals at 24 hours provided some evidence
that this group of animals had rapidly cleared bacteria
from the lungs and progressed to the repair of tissue
damaged during the localized response to infection.
Eight of the 13 genes whose expression was higher in
FR/C and FR/S at 24 hours encode ECM proteins.
Moreover, a number of these genes have previously
been shown to be transcribed in response to signalling
by members of the TGF-b family, the main group of
cytokines that co-ordinate the repair response [38-42].
Expression of fewer ECM components was higher in
FR/C and FR/S at 72 hours which might indicate that
the repair process had largely finished by this time. One
transcript whose expression was higher in ‘FR’ animals
was identical in sequence to the heavy chain constant
region of swine IgA, and the differential expression of
this gene was confirmed by RT-qPCR (see Figure 2).
The important role that IgA plays in protecting the host
against infection at mucosal surfaces is well documented
[43]. The short time-course of this experiment makes it
unlikely that this antibody could have been generated
through an adaptive immune response to infection. One
possibility is that this gene encodes a ‘natural antibody’.
Natural antibodies are high-avidity, low-affinity mole-
cules that bind conserved pathogen associated molecular
patterns (PAMPs) [44]. Their production does not
require T-cell help, so they are produced more quickly
in response to microbes than classical antibodies, and
are considered to be components of the innate immune
system. Although natural antibodies are principally of
the IgM class, natural IgA has been found at mucosal
surfaces in other species [45,46]. Interestingly, the poly-
meric immunoglobulin receptor (PIGR) gene, required
for the transport of secretory IgA to mucosal surfaces,
was found to be upregulated in ‘FR’ compared to ‘Con-
trol’ animals at 24 hours (see additional file 1). It is
likely that natural antibodies are important in protecting
the neonatal piglet from infection during a time at
which their adaptive immune systems are incompletely
developed [47]. However, the existence of a natural anti-
body producing subset of cells, such as the B1 cell char-
acterized in mice, has yet to be formally demonstrated
in swine [48]. The titres of neutralizing antibodies found
in neonatal animals have a genetic component, as
demonstrated by variation in the levels of natural anti-
body to vesicular stomatitis virus found in the sera of
different inbred mouse strains [49]. Consequently, poly-
morphisms in genes that control antibody production
could constitute one mechanism influencing susceptibil-
ity to H. parasuis infection.
A group of genes whose expression was lower in FR/C
and FR/S at 72 hours are involved in the transport and
metabolism of retinoids and lipids. This includes a
group of genes whose proteins either regulate, or are
regulated by, the transcription factor PPAR-g. PPAR-g, a
member of the PPAR family of lipid-binding nuclear
hormone receptors, functions as a heterodimer with
retinoid X receptors (RXRs) [50]. This transcription fac-
tor was first identified in man for its role in the differen-
tiation of adipocytes, but has subsequently also been
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shown to be a negative regulator of pro-inflammatory
(TNF-a, IL-1b) signalling by macrophages [51,52]. In
macrophages, activation of PPAR-g promotes the uptake
of lipids in the short term, in part through upregulation
of the scavenger receptor gene CD36. However, the
actions of CD36 in lipid uptake appear to be balanced
by lipid efflux co-ordinated by the PPAR-g target gene
Liver X Receptor (LXR) and effected by ABC type trans-
porters [53]. The mechanism by which PPAR-g blocks
pro-inflammatory signalling is not known, but the
absence of response elements in genes repressed by
PPAR-g agonists indicates that it is probably by trans-
repression of selected NF-B and AP-1 responsive genes
[54].
The gene expression profile of the ‘FR’ animals at 72
hours post-inoculation points to a reduction in PPAR-g
signalling, which would be expected to promote pro-
inflammatory activation of macrophages. One possibility
is that the expression profile reflected a basal difference
in macrophage gene expression which predisposed these
animals to a more rapid and effective antimicrobial
response at the critical early stage of infection. If this
were the case then genes involved in PPAR-g signalling
would be promising candidates for disease resistance
phenotypes. An alternative explanation is that PPAR-g
signalling was actively being switched off as the tissue
repair mechanisms evident in the ‘FR’ animals at 24
hours were completed. PPAR-g controls the ‘alternative’
activation of macrophages characterized by the release
of anti-inflammatory cytokines such as TGF-b during
tissue repair [55]. Irrespective of whether a reduction in
PPAR-g signalling is a cause or effect of the ‘Fully Resis-
tant’ phenotype, several of the most highly expressed
genes in ‘FR’ animals compared to ‘Control’ animals
encode components of the innate immune system.
These include the scavenger receptor ‘Deleted in malig-
nant brain tumour 1’ (DMBT1) and peptidoglycan
recognition protein 1 (PGLYRP1) (see additional file 1)
[56,57]. In addition, the role that natural antibodies may
play has already been discussed. Overall, these data sup-
port the hypothesis that the ‘Fully Resistant’ animals
actively cleared H. parasuis from the lungs before it
could be disseminated to other sites in the body. An
inevitable issue with this experiment was that in order
to confidently categorize H. parasuis-inoculated animals
as ‘Fully Resistant’, the animals had to be demonstrably
disease-free and have no detectable bacteria remaining
in the lungs. However, this approach precludes the
investigation of gene expression at earlier time-points
when bacteria are still present, which is unfortunate as
this is likely to be a time of critical importance in deter-
mining the ultimate outcome of infection. Determining
the genomic response to H. parasuis during these very
early stages of infection would help to identify more
gene candidates for resistance to Glässer’s disease, albeit
with the drawback that it would not be possible to clas-
sify the animals used into susceptibility categories.
In contrast to the ‘FR’ expression profile, many DE
genes were identified in the expression profile of ‘Sus-
ceptible’ animals, especially at the 72 hour time-point.
The profiles contain many genes whose differential
expression is likely to be a consequence of an ongoing
host response to H. parasuis infection. The most strik-
ing feature was the marked increase in the expression of
genes associated with inflammation: either encoding
components of signalling pathways associated with it (e.
g. cytokines, cytokine receptors), or proteins that func-
tion in the various biological processes encompassed by
the term (e.g. neutrophil phagocytosis, coagulation).
This finding is in agreement with the fibrino-purulent
pleuritis observed in the lungs of ‘Susceptible’ animals
[14]. The biological effects of many of the differentially
expressed signalling molecules are mediated by regula-
tion of the transcription factors NF-B and AP-1. Inter-
estingly, both pro and anti-inflammatory cytokine,
cytokine receptors, and intracellular components of
these signalling pathways are on the lists of differentially
expressed genes in the ‘Susceptible’ expression profiles.
To use signalling through the IL-1 receptor as an exam-
ple; the gene for the pro-inflammatory cytokine IL-1b
was more highly expressed in ‘Susceptible’ animals at 72
hours. However, the gene encoding its antagonist, IL-
1RN, was also more highly expressed, as was the gene
NFKBIA, whose product inhibits the NF-B complex. In
addition, the gene for Caspase-1 (CASP1), which is
required to process the IL-1b pro-protein into its active
form, was much less highly expressed in ‘Susceptible’
animals. In rats, expression of both IL-1B and IL1-RN is
induced by lipopolysaccharide (LPS), and the kinetics of
their activation indicates that IL-1RN likely acts as an
endogenous negative feedback regulator of IL-1b [58].
An imbalance of IL-1b and IL1-RN signalling has been
proposed as an important factor in several inflammatory
conditions in man such as asthma and arthritis [59,60].
It is noticeable that the most highly expressed genes in
‘Susceptible’ compared to ‘Control’ and ‘FR’ animals
(such as IL1B, RETN, and S100A9) encode cytokines
that promote inflammation. This suggests that endogen-
ous regulation mechanisms failed to keep the inflamma-
tory response in check in these animals, likely due to
pro-inflammatory stimuli caused by the continued
presence of H. parasuis.
An increase in pro-inflammatory cytokine gene
expression was also observed in the lungs of pigs
infected by Actinobacillus pleuropneumoniae, another
respiratory pathogen of pigs that is related to H. para-
suis [15], and the spleen of pigs infected with H. para-
suis [17]. The specific pro-inflammatory cytokines
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identified differ considerably between the three studies,
likely due to the differences in the microarrays used and
host-pathogen interactions. Common genes between
studies were the neutrophil chemokine IL8, identified in
both this study and that of Hedegaard et al. [15], and
the S100 proteins S100A9 and S100A12, and the resistin
(RETN) gene, which were all highly upregulated in
response to H. parasuis in the lung and spleen. Indeed,
RETN was the most upregulated gene in both our study
and that of Chen et al. [17]. First identified for its role
in adipocyte differentiation, its expression in leukocytes
and function as a pro-inflammatory cytokine has only
recently been recognized [61,62]. This study identified a
number of other genes in addition to RETN that func-
tion in the mobilization and biosynthesis of lipids, and
which are more highly expressed in ‘Susceptible’ ani-
mals. Several of these genes have also recently been
shown to have roles in human inflammatory disorders.
For example, LPL and SLC2A3 are expressed in the
“foamy” macrophages of atherosclerotic plaques [63,64].
These results implicate RETN and other lipid metabo-
lism genes in the pathogenesis of Glässer’s disease.
Novel drugs targeting these molecules could be promis-
ing treatments for reducing the severe immunopathol-
ogy associated with this, and perhaps other, infectious
diseases in the future.
Some genes whose expression is higher in S/C and S/
FR encode proteins of known antimicrobial activity.
Mutations affecting the function of any of these genes
could increase susceptibility to Glässer’s disease. Lacto-
transferrin (LTF) has both bacteriostatic and bactericidal
properties [65,66]. Although activity against H. parasuis
has not been demonstrated, LTF has been shown to
attenuate the pathologic potential of a related bacterium,
Haemophilus influenzae, a respiratory pathogen of man
[67]. Other genes with products of known antimicrobial
activity are CAMP, PTX3, and SLC11A1 [68-70].
Genes whose expression was lower in S/C and S/FR
include those that function in class I or class II antigen
presentation, T cell function, and immunoglobulin pro-
duction. Again, our results corroborate those obtained
by Hedegaard et al. [15] and Chen et al. [17], who also
found a reduction in expression of genes whose
products function in antigen presentation, albeit the
identities of the genes are different. During A. pleurop-
neumoniae infection, the MHC genes HLA-DRA and
HLA-DQA1 were found to be downregulated whereas in
the spleen of animals infected with H. parasuis it was
HLA-B and HLA-DRB1. In this study the differentially
expressed MHC genes identified were HLA-DMA, HLA-
DMB, and HLA-DRA. A reduction in the capability of
pigs to mount both cell-mediated and antibody based
responses to H. parasuis would clearly be expected to
have a detrimental effect on the ability of these animals
to clear infection. Chen et al. postulated that these
changes could be a consequence of an immune evasion
strategy employed by H. parasuis, and this is certainly a
possibility that warrants further research. An alternative
explanation supported by our results is that the
observed immunosuppression in the ‘Susceptible’ group
is caused by an increased production of IL-10, as this
cytokine strongly inhibits both class I and class II anti-
gen presentation [71,72]. IL10 gene expression was
increased in ‘Susceptible’ compared to ‘Control’ animals
at both 24 and 72 hours (see additional files 1 and 2).
One possibility is that this is a consequence of ‘endo-
toxin tolerance’, in which cells, particularly macro-
phages, become desensitised to repeated stimulation by
LPS. Tolerized cells upregulate the expression of anti-
inflammatory genes such as IL-10, IL1-RN, or TGFB1
[73]. Endotoxin tolerance is an important mechanism
for regulating an excessive inflammatory response, but it
comes at the cost of preventing the induction of strong
adaptive immune responses to infection. An increase in
the amount of IL-10 in the lung could also account for
the decrease in expression of genes regulated by type I
interferons. IL-10 inhibits production of IFN-a in per-
ipheral blood mononuclear cells in man in response to
herpes simplex virus (HSV) and vesicular stomatis virus
(VSV) [74,75].
Conclusions
This study has identified gene expression profiles asso-
ciated with host resistance and susceptibility to infection
by H. parasuis in CD piglets. The results support a sce-
nario in which ‘Fully Resistant’ animals rapidly elimi-
nated H. parasuis from the lung through an effective
innate immune response. The failure of ‘Susceptible’
animals to resolve the infection at an early stage resulted
in the systemic spread of the bacterium and the devel-
opment of lesions and clinical signs associated with
Glässer’s disease. Patterns of gene expression associated
with features of the molecular pathology of the disease
were identified in ‘Susceptible’ pigs: namely neutrophil
infiltration, fibrin deposition, and a predominance of
inflammatory cytokine production in the lung. In addi-
tion, a suppression of genes that encode proteins in
antigen presentation pathways was observed which
could have limited the ability of these animals to even-
tually mount a successful adaptive immune response to
infection. These results provide a valuable insight into
the host response to H. parasuis at the genomic level
and identify genes that are candidates for involvement
in disease resistance and susceptibility phenotypes.
Further investigation is warranted into the molecular
mechanisms governing these phenotypes and whether
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they operate in infections involving different strains of
H. parasuis or swine of different genetic backgrounds.
Methods
Bacterial challenge and selection of pigs for array
experiments
The tissue samples used for the experiments described
in this paper were collected as part of a previous study
[14]. Although the challenge protocol is described in
more detail in that paper, it is summarized below to
provide clarification on how animals were assigned
to susceptibility categories. This information is relevant
to the selection of pigs for microarray experiments.
Briefly, six boars from a commercial line (a Landrace-
Duroc synthetic) were mated with Landrace × Large
White sows. The offspring were removed immediately
after farrowing and deprived of maternal colostrum.
They were disinfected and then raised in an isolation
facility. Piglets at 21 days of age were inoculated intra-
tracheally with the pathogenic 29755 strain of H. para-
suis (serovar 5). Control animals were mock-inoculated
with phosphate buffered saline (PBS). Approximately
equal numbers of pigs were euthanized at 24, 48 and 72
hours post-inoculation. In total, 126 animals were
inoculated with H. parasuis and 29 with PBS. Animals
were inoculated in one of 10 independent challenge
experiments. Approximately 4-5 inoculated pigs and 1
mock-inoculated control animal were harvested at each
time-point in each experiment.
Animals were given a daily score of 0-3 based on the
presence and severity of 4 clinical signs associated with
Glässer’s disease (demeanour, respiratory problems,
lameness, and neurological signs). At necropsy, animals
were scored 0-3 for the presence and severity of 9 Gläs-
ser’s disease lesions (pleurisy, hydrothorax, pericarditis,
hydropericardium, peritonitis, ascites, meningitis, arthri-
tis, and pneumonia). Swabs were collected from 6 tissue
sites (pleura, pericardium, peritoneum, carpal joint, foot
joint, and meninges) and tested for H. parasuis by cul-
ture and PCR. Five mm2 lung tissue samples were col-
lected in RNA Later (Ambion) within 15 minutes of the
animal being killed and stored at - 80 °C. Samples were
selectively taken from areas of the lungs exhibiting Gläs-
ser’s disease lesions where present.
Each animal inoculated with bacteria was classified
into one of four categories for relative susceptibility to
Glässer’s disease: ‘Fully Resistant’ (FR), ‘Less Resistant’
(LR), ‘Less Susceptible’ (LS) and ‘Fully Susceptible’ (FS).
Animals exhibiting extremes of susceptibility, together
with mock-inoculated control animals, were chosen for
microarray experiments. The 6 ‘resistant’ animals chosen
for expression profiling were all classified as ‘Fully Resis-
tant’ (FR). ‘FR’ pigs were negative for H. parasuis by cul-
ture or PCR at all tissue sites, had lesions with a score
of 1 in no more than two tissues, or a total lesions score
of no more than 3 across 9 sites, and had clinical signs
with a score of 1 in no more than two categories. The
‘susceptible’ animals were selected to match the ‘FR’ ani-
mals for sire and time-point. Because of these restric-
tions, it was not possible to select 6 ‘FS’ animals: 4 ‘FS’
and 2 ‘LS’ animals were chosen and this group of 6 ani-
mals are referred to as ‘Susceptible’. These animals had
4 or more sites positive for H. parasuis by culture or
PCR, a total lesion score of at least 5 across 9 sites, and
a total clinical signs score of 3 or more. Mock-inocu-
lated ‘Control’ animals were negative for H. parasuis by
culture or PCR at all tissue sites, and had no lesions or
clinical signs associated with Glässer’s disease. They
were matched for sire with ‘FR’ and ‘Susceptible’ ani-
mals. It was not possible to use lung RNA from multiple
control animals for the same sire and time-point in the
pools as only one animal from each sire at each time-
point was designated as a ‘Control’ animal in the origi-
nal challenge experiments. Therefore pools were made
from RNA from ‘Control’ animals of the same sire but
different time-points (24, 48, and 72 hours). The animals
used in the microarray experiments are described in
more detail in Table 1. All animal procedures followed
regulations of the European Directive 86/609/CEE.
RNA extraction
RNA was extracted from lung tissue using Tri-Reagent
(Sigma Aldrich). The RNA samples were further purified
using an RNeasy mini kit (Qiagen) incorporating an on-
column digestion of DNA using RNase-free DNAse I
(Qiagen). RNA integrity was determined by electrophor-
esis on an Agilent 2100 Electrophoresis Bioanalyzer
(Agilent Technologies). Only samples with a 28:18 S
rRNA peak of > 1 were included in subsequent analyses.
Detection of H. parasuis by RT-PCR
A 500 ng amount of total RNA from each sample in a
20 μl volume was reverse-transcribed using Superscript
II reverse transcriptase (Invitrogen), and the remaining
RNA digested using RNase H (Invitrogen). PCR was car-
ried out using HotStar Taq polymerase (Qiagen) and
primers designed to generate an amplicon of 821 bp
from the 16 S rRNA gene of H. parasuis [19] using the
following conditions: 95°C for 15 minutes, followed by
37 cycles of 94°C for 30 seconds, 59°C for 30 seconds,
and 72°C for 150 seconds. A positive control PCR was
carried out using primers for the pig b-actin gene (For-
ward primer: 5′-TCCCTGGAGAAGAGCTACGA-3′;
Reverse primer: 5′-TGTTGGCGTAGAGGTCCTTC-3′)
generating an amplicon of 182 bp on cDNA and 280 bp
on genomic DNA (the primers were designed either side
of intron 4 of the pig gene). The reaction conditions
were: 95°C for 15 minutes, followed by 32 cycles of 94°C
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for 30 seconds, 57°C for 30 seconds, and 72°C for 30 sec-
onds. RT-PCRs were performed twice for each sample
with each primer pair.
Microarray labelling and hybridization protocols
Using a reference design, ‘target’ cDNA was prepared
from individual ‘FR’ and ‘Susceptible’ pigs and co-hybri-
dized to microarrays with reference cDNA made using
lung RNA from pools of mock-inoculated control ani-
mals. Four technical replicates (2 sets of dye-swaps) were
performed for each animal. The microarray used for this
study was the Pig Genome v1.0 + Extension set oligonu-
cleotide microarray (Operon). These arrays contained
13,297 70-mer probe sequences designed from The Insti-
tute for Genomic Research (TIGR) Sus scrofa Gene
Index (SsGI) database release 5.0 (2002). The probes
were printed in duplicate. Labelled cDNA targets were
prepared using a two step process. First, the target popu-
lation was amplified by RT-PCR using the SMART tem-
plate switching system (BD Biosciences). Second, the
PCR product was labelled with Cy3 or Cy5-dCTP (GE
Healthcare) using a Bioprime DNA Labelling System
(Invitrogen). A 500 ng amount of total RNA was mixed
with 10 pmol of 3’ SMART CDS primer IIA (5’-AAG-
CAGTGGTATCAACGCAGAGTAC-T30VN-3’) and 10
pmol template switching primer [5’-d(AAGCAGTGG-
TATCAACGCAGAGTACGC)r(GGG)-3’]. Reverse tran-
scription was carried out using ‘Powerscript’ reverse
transcriptase according to the manufacturer’s instructions
(BD Biosciences). PCR was performed using the first
strand cDNA as template with the following PCR primer
(5’-AAGAGT GGTATCAACGCAGAGT-3’) and HotStar
Taq (Qiagen). The conditions were: 95°C for 15 minutes,
then 18 cycles of 94°C for 30 seconds, 65°C for 30 sec-
onds and 68°C for 6 minutes. PCR products were puri-
fied using a MinElute PCR purification kit (Qiagen).
Purified PCR product in a random primer mix was dena-
tured at 95°C for 5 minutes. A low-dCTP mix (5 mM
dATP, dGTP, and dTTP; 2 mM dCTP), Cy3 or Cy5-
dCTP (1mM) (GE Healthcare) and 40 units of Klenow
polymerase (Invitrogen) were added and the reactions
incubated at 37°C for 2 hours. Labelled products were
purified using Autoseq G-50 columns (GE Healthcare).
Cy3 and Cy5-labelled target were combined with 4 μg of
Porcine Hybloc (Applied Genetic Laboratories), 8 μg of
poly dA oligonucleotide (Sigma-Genosys) and 4 μg of
yeast tRNA (Sigma-Aldrich). The DNA was ethanol pre-
cipitated and resuspended in 50 μl OpArray Hyb Buffer
(Operon) (final concentration of each dye was 0.8 pmol/
μl). Microarrays were pre-hybridized in OpArray Pre-hyb
buffer prior to hybridization. The labelled target DNA
was denatured at 65°C for 5 minutes then applied to the
array surface under a Lifterslip (Thomas Scientific).
Hybridizations were performed at 42°C for 15 hours.
Following hybridization, slides were washed using
Operon wash buffers and dried by centrifugation. Slides
were scanned using a GenePix 4100A Personal Scanner
(Axon Technologies) and signal intensities quantified
using Bluefuse 3.0 (Bluegnome). Features with irregulari-
ties affecting signal intensity were removed by manual
flagging and mean signal intensities for duplicate spots
were calculated.
Microarray data analysis
Microarray data were analyzed using ‘limma’ (linear
models for microarray analysis) [76]. Data were nor-
malized using a global Loess algorithm. Only genes
with data available from all hybridizations in the com-
parison of interest were used. A linear model was
fitted to the log2 transformed data to estimate variabil-
ity. For statistical analysis of differential gene expres-
sion, an empirical Bayes method was used to moderate
the standard errors of the log-fold changes. A Benja-
mani-Hochberg (BH) correction was applied to the p
values of the log fold changes to correct for multiple
testing [77]. Genes were categorized as differentially
expressed if they were ≥ 1.75 fold more or less highly
expressed in one group compared to the other and had
a BH adjusted p value of < 0.05. Sequences from dif-
ferentially expressed genes with no sequence annota-
tion were used to re-screen the non-redundant and
EST Genbank databases for gene matches using the
nucleotide BLAST algorithm [78]. The online software
tool ‘GoStat’ was used to identify human Gene Ontol-
ogy (GO) terms that were significantly over-repre-
sented in gene lists as compared to the genome as a
whole, indicating their potential importance to the
ascribed process [79].
Quantitative RT-PCR (RT-qPCR)
Two-step quantitative RT-PCR was performed on the
same total RNA samples used for the microarray experi-
ments. In total, RT-qPCR was carried out for 23 differ-
entially expressed genes and 3 reference genes. Primer
sequences are listed in additional file 5. The forward pri-
mer of each pair was designed to span a predicted
intron/exon splice junction in the pig gene (predicted by
alignment with the human RefSeq sequence). In addi-
tion, the primers were designed to exons present in all
reported splice variants of the human gene in the Entrez
Gene database at NCBI. First, 1 μg of total RNA was
reverse transcribed into first-strand cDNA using the
Quantitect Reverse Transcription kit (Qiagen) according
to the manufacturer’s recommended protocol. Real-time
PCR was carried out in triplicate using a 1/50 dilution
of each RT reaction, and once using a 1/10 dilution of
an RT negative control (an RT performed without
reverse transcriptase). PCR assays were carried out using
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the Quantitect SYBR green PCR kit (Qiagen) with 0.3
μM of each primer (Sigma-Genosys) in a 10 μl volume.
Reactions were run on a Rotorgene 3000 thermal cycler
(Corbett Research Ltd) using the following amplification
conditions: 95°C for 15 minutes, then 40 cycles of 94°C
for 15 seconds, X °C for 30 seconds and 72°C for 30
seconds, where X is between 54 and 57°C depending on
the primer pair used. A melt-curve analysis of each pri-
mer pair was carried out after PCR to verify the specifi-
city of the PCR assay. Reaction efficiencies and
quantification cycle (Cq) values were calculated by the
Rotorgene software using a standard curve derived from
real-time RT-PCR carried out on a 10-fold dilution ser-
ies of a standard consisting of RNA from ‘FR’, ‘Suscepti-
ble’, and ‘Control’ animals in equal proportions.
Analysis of RT-qPCR data
For each gene of interest, the mean Cq value of the
technical and biological replicates in the 2 groups being
compared (S v C, FR v C, FR v S, or S v FR) were deter-
mined. The relative expression value (Q) was calculated
using the delta Ct formula [80]. The values for Q and
its standard error were then adjusted by a normalization
factor calculated by determining the geometric mean of
the relative expression ratio for 3 reference genes [81]:
ribosomal large subunit protein 8 (RPL8), NADH dehy-
drogenase 1, beta subcomplex protein 10 (NDUFB10),
and Huntingtin interacting protein 1 (HIP1). These
genes were selected from the microarray results for
their stability of expression across all samples (< 1.12
fold differentially expressed). The statistical significance
of differential expression between the groups being
compared was determined by non-parametric randomi-
zation tests using REST 2005 software [82].
Additional material
Additional file 1: Lists of DE genes from the FR v C, S v C, FR v S
and S v FR gene expression comparisons at 24 hours post-
inoculation. The DE genes for each comparison are listed in separate
tabs of this Microsoft Excel file. Data for DE transcripts representing the
same gene are also listed in tabs. Annotation for each gene consists of
the SsGI identifier (IDs start TC), the Genbank Reference sequence
identifier and name of the best matched human gene, and the pig
oligonucleotide identifier and sequence. The data consist of Log2 gene
expression ratios and their associated variance and p values (both
corrected and uncorrected for multiple testing), in addition to none log-
transformed fold changes and amplitude of probe signal (signal
intensity).
Additional file 2: Lists of DE genes from the FR v C, S v C, FR v S
and S v FR gene expression comparisons at 72 hours post-
inoculation. The DE genes for each comparison are listed in separate
tabs of this Microsoft Excel file. Data for DE transcripts representing the
same gene are also listed in separate tabs. Annotation for each gene
consists of the SsGI identifier (IDs start TC), the Genbank Reference
sequence identifier and name of the best matched human gene, and
the pig oligonucleotide identifier and sequence. The data consist of Log2
gene expression ratios and their associated variance and p values (both
corrected and uncorrected for multiple testing), in addition to none log-
transformed fold changes and amplitude of probe signal (signal
intensity).
Additional file 3: Lists of DE genes from the expression profiles of
‘Fully Resistant’ animals at 24 and 72 hours post-inoculation. The
expression profiles of ‘Fully Resistant’ animals contain those genes that
are differentially expressed in both the ‘FR v C’ and ‘FR v S’ comparisons.
The expression profiles of ‘Fully Resistant’ animals at 24 and 72 hours
post-inoculation are shown on separate tabs. Data for DE transcripts
representing the same gene are also listed in separate tabs. Annotation
for each gene consists of the SsGI identifier (IDs start TC), the Genbank
Reference sequence identifier and name of the best matched human
gene, and the pig oligonucleotide identifier and sequence. The data for
each comparison consists of Log2 gene expression ratios and their
associated variance and p values (both corrected and uncorrected for
multiple testing), in addition to none log-transformed fold changes and
amplitude of probe signal (signal intensity).
Additional file 4: Lists of DE genes from the expression profiles of
‘Susceptible’ animals at 24 and 72 hours post-inoculation. The
expression profiles of ‘Susceptible’ animals contain those genes that are
differentially expressed in both the ‘S v C’ and ‘S v FR’ comparisons. The
expression profiles of ‘Susceptible’ animals at 24 and 72 hours post-
inoculation are shown on separate tabs. Data for DE transcripts
representing the same gene are also listed in separate tabs. Annotation
for each gene consists of the SsGI identifier (IDs start TC), the Genbank
Reference sequence identifier and name of the best matched human
gene, and the pig oligonucleotide identifier and sequence. The data for
each comparison consists of Log2 gene expression ratios and their
associated variance and p values (both corrected and uncorrected for
multiple testing), in addition to none log-transformed fold changes and
amplitude of probe signal (signal intensity).
Additional file 5: Primer sequences for RTqPCR. Primers were
designed from the pig expressed sequence tag (EST) sequence indicated.
Forward primers were designed over intron/exon boundaries predicted
from alignment of pig and human RefSeq sequence.
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